{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+IV+infusion&page=6", "query": { "intervention": "Placebo IV infusion", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 1858, "total_pages": 186, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+IV+infusion&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+IV+infusion&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T11:57:28.856Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00271765", "title": "A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myocardial Infarction" ], "interventions": [ { "name": "INO-1001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inotek Pharmaceuticals Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2004-01", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2006-11-29", "last_synced_at": "2026-10-11T11:57:28.856Z", "location_count": 10, "location_summary": "Fort Lauderdale, Florida • Valparaiso, Indiana • Saint Paul, Minnesota + 7 more", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Valparaiso", "state": "Indiana" }, { "city": "Saint Paul", "state": "Minnesota" }, { "city": "Newark", "state": "New Jersey" }, { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00271765" }, { "nct_id": "NCT03403751", "title": "Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Kidney Injury", "Peritonitis", "Necrotizing Soft Tissue Infection" ], "interventions": [ { "name": "Reltecimod 0.5 mg/kg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Atox Bio Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 58, "start_date": "2018-05-24", "completion_date": "2019-12-14", "has_results": true, "last_update_posted_date": "2021-10-12", "last_synced_at": "2026-10-11T11:57:28.856Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03403751" }, { "nct_id": "NCT00094653", "title": "MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma", "Metastases" ], "interventions": [ { "name": "MDX-010 (anti-CTLA4) monoclonal antibody", "type": "DRUG" }, { "name": "MDX-1379 (gp100) Melanoma Peptide Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1783, "start_date": "2004-09", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2011-07-11", "last_synced_at": "2026-10-11T11:57:28.856Z", "location_count": 110, "location_summary": "Tucson, Arizona • Duarte, California • Encinitas, California + 78 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00094653" }, { "nct_id": "NCT01934361", "title": "Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Glioblastoma Multiforme" ], "interventions": [ { "name": "buparlisib", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "lomustine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2014-02-28", "completion_date": "2016-07-07", "has_results": false, "last_update_posted_date": "2020-12-09", "last_synced_at": "2026-10-11T11:57:28.856Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Fayetteville, Arkansas • Chicago, Illinois + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01934361" }, { "nct_id": "NCT02989194", "title": "Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "VIS410 low dose", "type": "DRUG" }, { "name": "VIS410 high dose", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Visterra, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 150, "start_date": "2017-01-06", "completion_date": "2017-10-27", "has_results": true, "last_update_posted_date": "2022-08-15", "last_synced_at": "2026-10-11T11:57:28.856Z", "location_count": 11, "location_summary": "Huntsville, Alabama • Coral Gables, Florida • Homestead, Florida + 7 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Homestead", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02989194" }, { "nct_id": "NCT02709512", "title": "Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "ADI-PEG 20 plus Pem Platinum", "type": "DRUG" }, { "name": "Placebo plus Pem Platinum", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Polaris Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 249, "start_date": "2017-08-01", "completion_date": "2022-08-15", "has_results": true, "last_update_posted_date": "2023-10-04", "last_synced_at": "2026-10-11T11:57:28.856Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02709512" }, { "nct_id": "NCT00246012", "title": "A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Intetumumab", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centocor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2005-05", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2013-08-19", "last_synced_at": "2026-10-11T11:57:28.856Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00246012" }, { "nct_id": "NCT04356352", "title": "Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Injection Site Irritation", "Pain" ], "interventions": [ { "name": "Lidocaine", "type": "DRUG" }, { "name": "Esmolol", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 33, "start_date": "2020-09-09", "completion_date": "2023-08-25", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-11T11:57:28.856Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04356352" }, { "nct_id": "NCT03969004", "title": "Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cutaneous Squamous Cell Carcinoma" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 415, "start_date": "2019-06-04", "completion_date": "2028-01-07", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-10-11T11:57:28.856Z", "location_count": 40, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03969004" }, { "nct_id": "NCT03425643", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 797, "start_date": "2018-04-24", "completion_date": "2026-10-15", "has_results": true, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-11T11:57:28.856Z", "location_count": 51, "location_summary": "Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 45 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03425643" } ] }